<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>"Ozempic Face": What's Actually Happening to Your Face During Weight Loss – Élan Clinic</title>
  <meta name="description" content="Hollowed cheeks, loose skin, sunken eyes — "Ozempic face" is real, but it's not a drug side effect. A physician explains the biology of facial fat loss on GLP-1 medications and what actually prevents it." />
  <link rel="canonical" href="https://elan.clinic/blog/ozempic-face-why-glp1-changes-your-face.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/ozempic-face-why-glp1-changes-your-face.html" />
  <meta property="og:title" content=""Ozempic Face": What's Actually Happening to Your Face During Weight Loss" />
  <meta property="og:description" content="Hollowed cheeks, loose skin, sunken eyes — "Ozempic face" is real, but it's not a drug side effect. A physician explains the biology and what prevents it." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "\"Ozempic Face\": What's Actually Happening to Your Face During Weight Loss",
    "headline": "\"Ozempic Face\": What's Actually Happening to Your Face During Weight Loss",
    "url": "https://elan.clinic/blog/ozempic-face-why-glp1-changes-your-face.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "Hollowed cheeks, loose skin, sunken eyes — \"Ozempic face\" is real, but it's not a drug side effect. A physician explains the biology of facial fat loss on GLP-1 medications and what actually prevents it.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/ozempic-face-why-glp1-changes-your-face.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "STEP 1 DXA sub-study: body composition changes with semaglutide 2.4 mg",
        "isPartOf": { "@type": "Periodical", "name": "New England Journal of Medicine" },
        "datePublished": "2021"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "GLP-1 therapy body composition case series",
        "isPartOf": { "@type": "Periodical", "name": "PMC" },
        "datePublished": "2025"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .gold-line { width: 48px; height: 2px; background: #C5A55A; margin: 28px 0; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .key-stat__number { font-size: 2.4rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ═══ Navigation ══════════════════════════════════════════════════════ -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ═══ Breadcrumb ══════════════════════════════════════════════════════ -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">Ozempic Face</span>
      </nav>
    </div>
  </div>

  <!-- ═══ Article Header ══════════════════════════════════════════════════ -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Body Composition</span>
        <h1>"Ozempic Face": What's Actually Happening to Your Face During Weight Loss — and What You Can Do About It.</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            9 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ═══ Article Body ═════════════════════════════════════════════════════ -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <div class="pull-quote">
          <p>"The whole point of losing weight was to look and feel better. Now people keep asking if I'm sick." — r/Ozempic</p>
        </div>

        <p>
          I hear this more often than you might expect. A patient comes in having lost 18 kilograms. Their blood pressure is down, their joints feel better, their energy has transformed. And then, quietly, almost embarrassed, they tell me about their face. The hollowed cheeks. The skin that seems to hang differently. The way their eyes look slightly sunken now.
        </p>

        <p>They want to know if the medication did something wrong.</p>

        <p>It didn't. But the conversation they deserve — about what's happening and why — rarely happens in the fifteen minutes most clinical appointments allow. This article is that conversation.</p>

        <hr />

        <h2>What Is "Ozempic Face"?</h2>

        <p>
          "Ozempic face" is a tabloid term for something clinically real: the loss of facial volume that can accompany significant weight loss on GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound).
        </p>

        <p>
          The appearance can include gaunt or hollowed cheeks, deeper nasolabial folds (the lines running from nose to mouth), looser skin around the jawline, and a generally more aged look. It's alarming when it happens, especially because the rest of the body transformation may feel like a victory.
        </p>

        <p>
          Here's the most important thing I can tell you as a physician: <strong>this is not a drug side effect. It is a fat loss effect.</strong>
        </p>

        <p>
          GLP-1 medications don't selectively damage your face. They create the metabolic conditions for significant fat loss across your entire body — including the subcutaneous fat depots that give the face its youthful fullness. The same process would occur with any equivalent caloric deficit achieved through diet alone. The difference is that GLP-1-induced weight loss often happens faster and more substantially than patients have previously managed, which means the facial changes can be more pronounced.
        </p>

        <hr />

        <h2>The Biology: Why the Face Changes First (and Most Visibly)</h2>

        <p>
          Your face contains several distinct fat compartments — anatomists call them fat pads — distributed across the temples, cheeks, under the eyes, and along the jawline. These pads give the face its characteristic three-dimensional structure. They're also metabolically active: when the body enters a sustained caloric deficit, it draws on fat stores throughout the body, and facial fat pads are not exempt.
        </p>

        <p>
          The STEP 1 DXA sub-study — a pre-specified imaging analysis from the landmark semaglutide phase 3 trial — gives us the clearest picture of what fat loss looks like across the whole body. In participants treated with semaglutide 2.4 mg, <strong>total fat mass fell by 19.3%</strong>, and visceral (deep abdominal) fat fell by 27.4%. Absolute lean body mass decreased by 9.7%, but as a proportion of total body weight, lean mass actually <em>increased</em> by 3 percentage points — meaning the body was losing predominantly fat, not muscle.
        </p>

        <p>That 19.3% total fat reduction doesn't stay neatly in the abdomen. Regional fat loss is systemic, which means the face, neck, and upper chest also experience significant volume reduction.</p>

        <p>Why does this affect the face so visibly compared to, say, the thighs? Three reasons:</p>

        <p>
          <strong>1. There's less to lose.</strong> Facial fat pads are relatively small. A modest absolute loss represents a large relative change. Losing 500 grams of facial fat is barely noticeable on a body scan, but it can substantially alter the geometry of a face.
        </p>

        <p>
          <strong>2. Skin elasticity is age-dependent.</strong> Younger skin — rich in collagen and elastin — can contract to accommodate a smaller underlying volume. From around the age of 35, collagen synthesis declines at roughly 1% per year. The skin becomes less capable of recoil. A 55-year-old who loses the same amount of facial fat as a 30-year-old will show it far more obviously.
        </p>

        <p>
          <strong>3. Rate of loss matters enormously.</strong> Skin adapts gradually when given time. Slow weight loss — roughly 0.5% of body weight per week — allows the dermal layers to contract incrementally. Rapid loss outpaces that adaptation. The fat pad reduces faster than the overlying skin can follow, leaving what patients describe as a "deflated" appearance.
        </p>

        <hr />

        <h2>Who Is Most at Risk?</h2>

        <p>Not everyone who loses significant weight on GLP-1 therapy will experience notable facial changes. The patients I've observed to be most vulnerable share several characteristics:</p>

        <p>
          <strong>Age over 50</strong>, where collagen reserve is lower and skin is already less elastic; <strong>rapid weight loss</strong> exceeding 1% of body weight per week; <strong>protein intake below threshold</strong> — insufficient dietary protein during active weight loss accelerates loss of lean tissue, including the structural proteins that support skin; <strong>no resistance training</strong> — muscle mass provides scaffolding throughout the body, and its absence allows greater soft tissue descent; and <strong>pre-existing skin laxity</strong> — sun damage, smoking history, and prior significant weight fluctuations all compromise the skin's ability to adapt.
        </p>

        <hr />

        <h2>What the Evidence Says About Prevention</h2>

        <p>
          There's an important nuance in the STEP 1 data that often gets lost in lay coverage: the proportion of lean mass <em>improved</em> even as absolute lean mass fell. This reflects the fundamental principle that the <em>quality</em> of a weight loss programme shapes its body composition outcome — not just the drug itself.
        </p>

        <p>
          A 2025 case series (PMC12536186) examined body composition outcomes in three patients on GLP-1 therapy with very different results. Patient 2 lost 26.8% of body weight but actually <em>gained</em> 2.5% lean mass. Patient 3 lost 13.2% of body weight and gained 5.8% lean mass. The differentiator was not the drug dose or duration. It was what they did alongside the medication: adequate dietary protein and consistent resistance training.
        </p>

        <p>That finding has significant implications for facial appearance. Lean tissue preservation — including the structural protein matrix beneath the skin — depends on these two interventions.</p>

        <h3>1. Manage the Rate of Loss</h3>

        <p>
          A well-supervised GLP-1 programme aims for 0.5–1.0% of body weight loss per week. Slower is not worse — it is, in many respects, better. It allows skin more time to adapt, preserves more lean tissue proportionally, and reduces the magnitude of facial change. If the scale is moving faster than this, it's worth reviewing dose titration with your physician.
        </p>

        <h3>2. Prioritise Protein</h3>

        <p>
          The minimum threshold for lean mass preservation during active weight loss is <strong>1.2 grams of protein per kilogram of body weight per day</strong>. For meaningful protection, the target is 1.6 g/kg. This applies directly to facial tissue: collagen synthesis requires adequate amino acid supply, and a diet chronically deficient in protein during weight loss will compromise skin structural integrity.
        </p>

        <p>
          The practical challenge is that GLP-1 medications suppress appetite, sometimes dramatically. Patients may eat so little that protein targets slip. If your appetite is very suppressed, prioritise protein in every meal before anything else.
        </p>

        <h3>3. Resistance Train — Consistently</h3>

        <p>
          The Cell Reports Medicine commentary (2025) put it plainly: <em>"Resistance exercise should be standard co-prescription with GLP-1 therapy — not optional add-on."</em>
        </p>

        <p>
          Resistance training preserves lean mass throughout the body during caloric deficit. It doesn't directly prevent facial fat loss, but it preserves the muscular scaffolding and metabolic rate that influence overall tissue quality. Three sessions per week of compound movements — squats, deadlifts, rows, presses — is the minimum effective dose.
        </p>

        <h3>4. Support the Skin Directly</h3>

        <p>
          The evidence for topical interventions is modest, but the risk is essentially zero. Daily moisturisation, consistent SPF use (UV exposure degrades collagen), and adequate hydration all support skin resilience during weight loss. Collagen peptide supplementation has shown marginal benefit in some trials — I don't prescribe it specifically, but I don't discourage patients who wish to use it.
        </p>

        <hr />

        <h2>The Part Nobody Talks About: Identity After Transformation</h2>

        <p>There's a psychological dimension here that pure physiology doesn't capture.</p>

        <div class="pull-quote">
          <p>"I still see myself as big. I can't seem to wrap my head around the changing size of my body." — r/Ozempic (off medication one year, down two clothing sizes)</p>
        </div>

        <p>
          Significant weight loss — regardless of how it's achieved — disrupts identity. The person in the mirror looks unfamiliar. The face that changed can heighten that disorientation. For many patients, the body dysmorphia runs in both directions: still seeing themselves as large when they're not, or seeing the new facial changes as "wrong" even when the overall health trajectory is excellent.
        </p>

        <p>
          This is real, it's documented, and it deserves clinical attention alongside the physical changes. I check in with my patients about how they feel about their changing appearance, not just what the scale shows.
        </p>

        <hr />

        <h2>The Physician's Summary</h2>

        <p>
          "Ozempic face" is a real phenomenon with a real biological explanation. It is not an adverse drug reaction. It is the natural consequence of significant, systemic fat loss in a structure where fat loss is immediately visible and where skin elasticity may be limited.
        </p>

        <p>
          The risk is higher in older patients and those losing weight rapidly without adequate protein and resistance training. It is substantially mitigated by the same protocol that protects body composition everywhere else: supervised rate of loss, sufficient dietary protein, and consistent strength training.
        </p>

        <p>
          GLP-1 therapy is one of the most effective metabolic interventions we have. Getting the most from it — for your metabolic health and your appearance — requires treating it as a complete programme, not just a prescription.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">19.3%</div>
          <div class="key-stat__label">Total fat mass reduction seen in the STEP 1 DXA sub-study with semaglutide 2.4 mg — systemic fat loss that includes facial fat pads, not just abdominal fat.</div>
        </div>

        <!-- ═══ Sources ═══════════════════════════════════════════════════ -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." <em>New England Journal of Medicine</em>, 2021 (STEP 1 trial including DXA sub-study).</p>
          <p>PMC12536186. Body composition case series: GLP-1 therapy with resistance training and protein optimisation, 2025.</p>
          <p>Cell Reports Medicine commentary. "Resistance exercise as co-prescription with GLP-1 therapy," 2025.</p>
        </div>

        <!-- ═══ Back Link ═════════════════════════════════════════════════ -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ═══ Footer CTA ══════════════════════════════════════════════════════ -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>On GLP-1 Therapy? Get a Complete Programme.</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation to build a protocol around your medication — body composition monitoring, protein targets, and strength training — so the weight loss works for your whole body.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ═══ Footer Legal ════════════════════════════════════════════════════ -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
